炎症性肠病患儿抗TNF-α治疗过程中的侵袭性感染  

Invasive infections related to anti-TNF-αtherapy in pediatric inflammatory bowel disease

作　　者：郑璐(综述) 王怡仲[1] 李小露 张婷(审校)[1] Zheng Lu;Wang Yizhong;Li Xiaolu;Zhang Ting(Department of Gastroenterology and Infectious Diseases,Children′s Hospital,Shanghai Jiao Tong University,Shanghai 200062,China)

机构地区：[1]上海交通大学附属儿童医院消化感染科,200062

出　　处：《国际儿科学杂志》2021年第4期222-225,共4页International Journal of Pediatrics

基　　金：国家自然科学基金项目(81870373)。

摘　　要：抗肿瘤坏死因子-α(anti-tumor necrosis factor-α,anti-TNF-α)制剂已广泛用于儿童炎症性肠病(inflammatory bowel disease,IBD)的治疗。抗TNF-α治疗可有效诱导和维持IBD患儿的病情缓解,促进肠道黏膜愈合,预防长期的终末期器官损伤和生长发育滞后。但由于抗TNF-α治疗会显著抑制机体免疫功能,从而导致接受抗TNF-α治疗IBD患儿的感染风险增加,包括细菌、病毒、真菌、分枝杆菌的感染等。该文就抗TNF-α制剂治疗过程中IBD患儿发生感染的文献进行综述,以提高儿科医护人员对IBD患儿抗TNF-α治疗过程中发生继发感染的认知。Anti-tumor necrosis factor-α(anti-TNF-α)agents have been widely used in the treatment of inflammatory bowel disease(IBD)in children.Anti-TNF-αtherapy can effectively induce and maintain disease remission,promote intestinal mucosal healing,and prevent long-term end-stage organ damage and growth retardation in pediatric IBD patient.Anti-TNF-αagents can significantly impair the human immune function,which may increase the infection risk of IBD children,including the infection of bacteria,viruses,fungi and mycobacteria.This study summarizes the current published literature regarding infections in pediatric patients with IBD receiving anti-TNF-αtherapies,which can help to improve the cognition of pediatric medical staff on opportunistic infection of pediatric IBD patients following anti-TNF-αtreatment.

关 键 词：儿童 抗TNF-α治疗 炎症性肠病 感染 

分 类 号：R57[医药卫生—消化系统]